8-K: ReShape Lifesciences Enacts 1-for-25 Reverse Stock Split to Boost Share Price

ReShape Lifesciences implemented a 1-for-25 reverse stock split, effective May 9, 2025, to increase its stock price and maintain Nasdaq compliance.

Summary

• ReShape Lifesciences Inc. has enacted a 1-for-25 reverse stock split of its common stock.
• The reverse stock split became effective for trading purposes on May 9, 2025.
• Every 25 shares of issued and outstanding common stock were converted into one share.
• Fractional shares resulting from the split were rounded up to the nearest whole share.
• Proportional adjustments were made to the number of shares issuable upon exercise or conversion of warrants, stock options, and convertible preferred stock.
• The reverse stock split does not reduce the number of authorized shares of common stock and preferred stock.
• The reverse stock split was approved by the company's stockholders on April 1, 2025.
• ReShape Lifesciences stockholders will receive instructions from the company's transfer agent, Equiniti Trust Company, LLC, as to procedures for exchanging existing stock certificates for new certificates or book-entry shares.
• The new CUSIP number for the company's common stock following the reverse stock split will be 76090R408.

Sentiment

Score: 4

Explanation: The announcement of a reverse stock split is generally viewed with caution by investors, as it often signals underlying financial difficulties. While the company presents it as a strategic move, the market's reaction will depend on whether ReShape Lifesciences can demonstrate improved performance.

Positives

• The reverse stock split aims to increase the market price of ReShape Lifesciences' common stock.
• The reverse stock split does not reduce the number of authorized shares of common and preferred stock, providing flexibility for future capital raising activities.

Negatives

• Reverse stock splits are often viewed negatively by investors as they can indicate financial distress or an attempt to artificially inflate the stock price.

Risks

• The reverse stock split may not be successful in maintaining Nasdaq compliance or attracting new investors.
• The company's stock price could decline further if the underlying business performance does not improve.

Future Outlook

The company expects the reverse stock split to increase its stock price and maintain compliance with Nasdaq listing requirements.

Management Comments

• ReShape Lifesciences President and Chief Executive Officer, Paul F. Hickey, is the contact for investor relations.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low share prices; however, their effectiveness varies depending on the company's underlying financial health and future prospects.

Comparison to Industry Standards

• Other companies in the biotech and medical device industries have used reverse stock splits to regain compliance with listing requirements, such as Titan Pharmaceuticals and Diffusion Pharmaceuticals.
• The success of a reverse stock split depends on the company's ability to improve its financial performance and investor confidence following the split.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but the value of their holdings should remain approximately the same immediately following the split.
• The reverse stock split could impact investor confidence and trading volume in the short term.

Next Steps

• ReShape Lifesciences stockholders will receive instructions from Equiniti Trust Company, LLC, regarding the exchange of existing stock certificates.
• The company will monitor the impact of the reverse stock split on its stock price and Nasdaq compliance.

Key Dates

Keywords

reverse stock split, ReShape Lifesciences, RSLS, common stock, stockholders, Nasdaq, stock price